シャドーイング練習: Accurately Diagnosing the Soft Tissue Sarcoma - YouTubeで英語スピーキングを学ぶ
C2
You know, as our lead surgeon and one of the lead surgeons in the world,
148 文
文が短すぎたり長すぎる場合は、Editをタップして調整してください。
1
You know, as our lead surgeon and one of the lead surgeons in the world,
2
I think it's always, you know,
3
very important that our surgical colleagues are dramatically involved in the treatment of sarcoma
4
because usually you're the gatekeeper in the entrance of a lot of this.
5
And so, you know, I think it would be good to ask you what your typical workup is for a patient
6
is suspected of having a sarcoma.
7
Sure, thanks, Brian.
8
You know, it's generally a patient will present to a primary care doctor
9
or an orthopedic surgeon or a general surgeon with a mass that is growing,
10
something that is changing, or maybe abdominal distension and discomfort.
11
But like we all learn in medical school,
12
a good history in physical is the first thing we do.
13
If this mass has been there for a long time,
14
it's less likely to be a malignant process or an aggressive malignant process.
15
If it's rapidly changing, the acuity is obviously there and something needs to be done about it.
16
But it's very important to stress the history and physical.
17
I always joke with my trainees that the most important test we order is the history and physical.
18
With that being said, we generally do recommend plain film imaging,
19
radiographs, orthogonal views in the extremity particularly,
20
because that can shed a lot of information in the area of cost containment.
21
If it's completely radiolucent in an extremity film,
22
it is very likely to be lipomatous,
23
well-differentiated liposarcoma at the worst,
24
versus if it has some calcifications on it,
25
the acuity is probably there and that it's a synovial sarcoma or potentially a higher grade liposarcoma,
26
things of that sort.
27
So radiographs are important and they're inexpensive.
28
Beyond that, we do think that advanced imaging is important before any biopsy is done.
29
We generally recommend an MRI in the extremity,
30
sometimes in the pelvis, but often a CT is adequate.
31
And if we really suspect that it's a sarcoma,
32
we prefer getting a chest CT first before any intervention is done.
33
But if you're seeing the patient in the clinic
34
and you're going to do a biopsy in the clinic because it's amenable to that,
35
you can hold off on some of that advanced imaging.
36
But we certainly recommend getting advanced imaging of the primary before any intervention is done.
37
As we all will talk about,
38
the most common site for these metastases is the chest,
39
and so we do think chest imaging is of paramount importance.
40
No, I agree, and I think it's always important to remember that,
41
you know, we hear lots of interesting things and you know,
42
car doors do not cause hematomas unless you're on blood thinners.
43
And so, you know, it's very important to always do that history and physical,
44
because these masses sometimes just get found by car doors.
45
Otherwise, you know, surgeons go and explore in the middle of a sarcoma,
46
and if you don't do these right,
47
I mean, you can get inferior outcomes.
48
And so, I mean, as we're moving through from the history and physical to imaging,
49
I think the next most important thing is really an understanding of diagnosis
50
and grading of these tumors and really what that means.
51
And I think maybe Dr. Jones can give us a little insight about how they approach that.
52
Thank you.
53
So as Dr. Patel mentioned,
54
these are heterogeneous and a complex group of diseases.
55
So it's very important to obtain a clear and accurate histological diagnosis prior to starting treatment.
56
Each histological subtype can have different clinical behavior due to different underlying biology and can also have a different treatment approach.
57
So it's important to have an experienced pathologist make the diagnosis prior to starting treatment.
58
The World Health Organization classification system is generally regarded as the standardized publication for classifying these tumors.
59
and it's very important that newer techniques such as molecular techniques are incorporated into the diagnosis as well.
60
In terms of grading, the most common grading system that's used is the French,
61
so-called French grading system, incorporating three grades,
62
high, intermediate and low, based on tumor differentiation, necrosis and mitotic count.
63
and the grading system has implications in terms of prognosis.
64
I think that's really, really important.
65
And, you know, in the year 2015 with our ability to sequence everybody
66
and our ability to look at all sorts of molecular markers,
67
you know, I think we're into a very complex world and a very rare group of tumors.
68
And so, you know, Jonathan,
69
what is your goals of molecular testing and how do you incorporate that into your practice?
70
Good question.
71
And thank you for the invitation to participate in the panel.
72
And I agree with, certainly with Shreyas and Robin,
73
regarding the complexity of sarcomas.
74
In fact, there's over 200 different types,
75
if you look at the pathology textbooks.
76
And I think that molecular testing is underutilized in the world of sarcoma and that it can help in diagnosis.
77
For instance, there are a number of histologies
78
that have specific genetic abnormalities such as gene amplification and MDM2 and some of the liposarcomas,
79
de-differentiated and well-differentiated.
80
And this testing can not only help make the diagnosis,
81
but there could also be therapeutic relevance.
82
For instance, in the era of targeted therapies,
83
we are now able to pair specific molecular events such as
84
a mutation in a gene called KIT in GI stromal tumor with a therapy such as imatinib
85
or sunitinib or regorafenib and be able to really precisely treat patients based on the molecular rearrangements or abnormalities.
86
And this is particularly pertinent to sarcoma since we have
87
so many histologic subtypes that have a very high frequency of these molecular abnormalities.
88
So, Brian, if I could add a few comments with this too.
89
I think has been well stated.
90
It's a huge number of different tumors.
91
And just like you would never classify carcinomas as one disease,
92
you wouldn't lump breast carcinoma and prostate carcinoma into the same thing.
93
We do that in sarcomas where we have these different diseases.
94
We lump together sarcomas because they're so rare and they can have similar presentations but markedly different genetics and different behavior.
95
And one of the key parts is to make sure,
96
as Robin was saying, that an expert in sarcoma pathologies reviewing the material,
97
especially
98
when it's obtained at a community hospital where pathologists may only
99
see a few cases of these in the course of their career.
100
The hierarchical testing that they do is based not just on the specimen they have,
101
but also based on the presentation of the patient.
102
So it's also very important that the medical
103
and surgical teams are in communication with the pathologist about the location of the tumor,
104
the behavior of the tumor, and those other aspects.
105
So a multidisciplinary approach is really important.
106
And their testing often looks at the shape of the cells first and where it is located,
107
and then that helps drive other testing like immunistic chemistry and other molecular testing.
108
I think we're still very early in the question of the wide-scale genomic testing that's performed either for research
109
or for clinical commercial purposes right now.
110
In our experience, and I think a lot of the other centers are doing this as well,
111
where we've sequenced large panels of genes,
112
we've seen a disappointingly few number of mutations that we didn't already expect in sarcomas.
113
I think it's still a very important area for research,
114
but personally I'm not yet ready to order huge screening panels for genetic mutations,
115
but instead stay focused, as John was just talking about based on the appearance of the tumor,
116
suspected appearance of the tumor,
117
and the possible mutation types.
118
Dr. Yeah, I'd like to,
119
if I may, an illustrative example is in the pediatric realm of a very practical fusion product,
120
you know, the fusion-associated tumors,
121
rhabdomyosarcoma, where historically it's been either in pediatric realm, conventionally alveolar versus embrinal.
122
And now it's actually fusion-driven,
123
and that's the gold standard.
124
And if there's some Pax-Foxo associated tumor that may have some embryonal features,
125
they're still going to call it alveolar.
126
And it's really that and the clinical trials moving forward through the Children's Inchology Group,
127
et cetera, are all doing this.
128
And I think Synovial and Ewings are following suit with that.
129
So it's really boots on the ground.
130
This is happening today, not just some academic ivory tower concept.
131
And I'd like to just highlight the importance of a multidisciplinary team in making the diagnosis.
132
Andy said, very often it's important to have the clinical features
133
and the radiological features together with the pathology to make the diagnosis.
134
And that's really, really important to highlight.
135
I think it's important to highlight the fact that the one thing that these are all mistaken for are melanomas,
136
and melanomas are, you know, they're mistaken for sarcomas.
137
And if you really make that error,
138
you've altered radically a treatment path for a patient.
139
And this is why having a highly experienced sarcoma pathologist confirming what they're seeing is really that important.
140
And what's very interesting is it's very hard,
141
I believe, to have the discussion we're having today
142
because we're talking about at least 80 different diseases that probably break up in six different categories of each one.
143
And we go from probably one of the best understood tumors on the planet,
144
which is the GI stromal tumor,
145
where we understand what mutations go with what drug,
146
to the undifferentiated pleomorphic sarcoma,
147
where we're still doing lots of clinical trials,
148
which we'll get into later.
アプリをダウンロード
話したすべての文をAIが採点
TRENDING
人気動画
この動画で話す練習をする理由は？
この動画は、軟部組織肉腫の診断や治療に関する専門的な内容を扱っています。外科医や医療従事者たちの会話を通じて、患者の診療プロセスを学ぶことで、医療英語や専門用語を効果的に身に付けることができます。英語を話す練習をすることで、正確な語彙や文法を理解し、自信を持って英語を話せるようになるための良い機会です。また、同時に医療現場でのコミュニケーション能力を高めることができます。
文法と表現の文脈
- It's generally a patient will present to... - この構文は、一般的な患者の流れを説明するために使用されます。「一般的に患者は〜に来る」と訳すことができます。
- It's very important to stress the history and physical. - ここでは、「歴史と身体検査の重要性を強調することが非常に重要です」と示し、医療でのプロセスをクリアに説明しています。
- If it's rapidly changing,... - この条件文は、状況が変化した場合の判断を説明に役立ちます。「もし急速に変化しているなら、」と訳せます。
このような文法構造を理解することで、IELTSスピーキング対策にも役立ちます。これらの表現は、特に専門的な会話の中で重要です。
よくある発音の罠
動画内での発音には、特に注意が必要な単語やフレーズがあります。例えば、「sarcoma」や「radiographs」といった術語は、英語話者でも混乱しがちな言葉です。これらの単語を正しく発音する練習は、英語スピーキング練習において非常に有益です。さらに、会話の速さや抑揚にも注意を払い、「shadow speak」技法を活用することで、自然な発音を身につけることができます。特に医療英語においては、正確な発音が求められます。
シャドーイングとは？英語上達に効果的な理由
シャドーイング（Shadowing）は、もともとプロの通訳者養成プログラムで開発された言語学習法で、多言語習得者として知られるDr. Alexander Arguelles によって広く普及されました。方法はシンプルですが非常に効果的：ネイティブスピーカーの英語を聞きながら、1〜2秒の遅延で声に出してすぐに繰り返す——まるで「影（shadow）」のように話者を追いかけます。文法ドリルや受動的なリスニングと異なり、シャドーイングは脳と口の筋肉が同時にリアルタイムで英語を処理・再現することを強制します。研究により、発音精度、抑揚、リズム、連音、リスニング力、そして会話の流暢さが大幅に向上することが確認されています。IELTSスピーキング対策や自然な英語コミュニケーションを目指す方に特におすすめです。